The list below is only a partial list of FDA approved targeted therapies:
Targeted Therapy |
Mechanism of Action |
Indications |
| Avastin [Bevacizumab] |
Humanized monoclonal antibody against vascular endothelial growth factor [VEGF]. |
First-line treatment of metastatic colorectal cancer. |
Erbitux [Cetuximab] |
Chimeric monoclonal antibody against epidermal growth factor receptor [EGFR |
First line treatment of metastatic colorectal cancer. |
Tarceva
[Eriotnib] |
Monoclonal antibody against epidermal growth factor receptor [EGFR]. |
Non small cell lung cancer. |
Iressa
[Gefitinib] |
Tyrosine kinase inhibitor. |
Third-line treatment of non-small cell lung cancer. |
| Herceptin [Trastuzumab] |
Humanized monoclonal antibody against HER2. |
Metastatic breast cancer expressing HER2. |
Newhouse, Joseph P., Mendelsohn, John, M.D., Gelband, Helen, Herdman, Roger, Federal Agency Roles in Cancer Drug Development from Preclinical Research to New Drug Approval: The National Cancer Institute and the Food and Drug Administration, 3-4; [March 2005].
Reprinted, courtesy of the National Cancer Institute
Treatment of Recurrent Disease: Questions and Answers About Angiogenesis Inhibitors
Q&A By Deborah Armstrong, M.D., Medical Oncologist at Johns Hopkins
|
